Combi-TED: A new Trial Testing Tedopi^® with Docetaxel or Nivolumab in Metastatic Non-Small-Cell Lung Cancer Progressing After First Line

References

• Siegel RL , MillerKD, JemalA. Cancer statistics, 2020.CA Cancer J. Clin.70(1), 7–30 (2020).
   PubMed Web of Science ®Google Scholar
• Esfahani K , RoudaiaL, BuhlaigaN, DelRincon SV, PapnejaN, MillerWHJr. A review of cancer immunotherapy: from the past, to the present, to the future.Curr. Oncol.27(Suppl. 2), S87–S97 (2020).
   PubMedGoogle Scholar
• Dong H , StromeSE, SalomaoDRet al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793–800 (2002).
   PubMed Web of Science ®Google Scholar
• Butte MJ , KeirME, PhamduyTBet al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1), 111–122 (2007).
   PubMed Web of Science ®Google Scholar
• Siciliano MA , CaridàG, CilibertoDet al. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis. ESMO Open 7(3), 100465 (2022).
   PubMed Web of Science ®Google Scholar
• Lim SM , HongMH, KimHR. Immunotherapy for non-small cell lung cancer: current landscape and future perspectives.Immune Netw.20(1), e10 (2020).
   PubMed Web of Science ®Google Scholar
• Mielgo-Rubio X , UribelarreaEA, CortésLQ, MoyanoMS. Immunotherapy in non-small cell lung cancer: update and new insights.J. Clin. Transl. Res.7(1), 1–21 (2021).
   PubMedGoogle Scholar
• Gandhi L , Rodríguez-AbreuD, GadgeelSet al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378(22), 2078–2092 (2018).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L , LuftA, VicenteD, TafreshiAet al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379(21), 2040–2051 (2018).
   PubMed Web of Science ®Google Scholar
• Socinski MA , JotteRM, CappuzzoFet al. Atezolizumab for first-line treatment of metastatic non-squamous NSCLC. N. Engl. J. Med. 378(24), 2288–2301 (2018).
   PubMed Web of Science ®Google Scholar
• Planchard D , PopatS, KerrKet al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl. 4), iv192–iv237 (2018).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency: Taxotere (docetaxel) summary of product characteristics (2022). www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf
   Google Scholar
• Neal JW , KunduP, TanakaTet al. A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy. J. Clin. Oncol. 39, TPS9134 (2021).
   Google Scholar
• Leighl NB , HuiR, Rodriguez-AbreuDet al. Abstract CT289: pembrolizumab plus lenvatinib vs docetaxel in patients with previously treated metastatic non-small-cell lung cancer (NSCLC) and PD after platinum-doublet chemotherapy and immunotherapy: phase 3, randomized, open-label LEAP-008 trial. Cancer Res. 80(Suppl. 16), CT289 (2020).
   Google Scholar
• Clinicaltrial gov NCT03906071 . Phase 3 study of sitravatinib plus nivolumab vs docetaxel in patients with advanced non-squamous non-small cell lung cancer (SAPPHIRE).https://clinicaltrials.gov/ct2/show/NCT03906071
   Google Scholar
• Reck M , KaiserR, MellemgaardAet al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15(2), 143–155 (2014).
   PubMed Web of Science ®Google Scholar
• Garon EB , CiuleanuTE, ArrietaOet al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384(9944), 665–673 (2014).
   PubMed Web of Science ®Google Scholar
• Pal SK , McGregorB, SuárezCet al. Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study. J. Clin. Oncol. 39(33), 3725–3736 (2021).
   PubMed Web of Science ®Google Scholar
• Reckamp KL , RedmanMW, DragnevKHet al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A. J. Clin. Oncol. 40(21), 2295–2307 (2022).
   PubMed Web of Science ®Google Scholar
• Grohe C , ZanderI, Lüdtke-HeckenkampKet al. 3255 – Nintedanib plus docetaxel in routine clinical practice: VARGADO – a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape. Ann. Oncol. 29(Suppl. 8), viii493–viii547 (2018).
   Google Scholar
• Barve M , BenderJ, PappenBet al. Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients. J. Clin. Oncol. 26(Suppl. 15), 8057 (2008).
   Web of Science ®Google Scholar
• Giaccone G , FelipE, CoboMet al. Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI), Step 1 results of phase III ATALANTE-1 randomised trial. Ann. Oncol. 31, S814–S815 (2020).
   Google Scholar
• Besse B , GarciaCampelo MR, CoboDols MAet al. LBA47 – Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): final results of phase III Atalante-1 randomised trial. Ann. Oncol. 32(Suppl. 5), S1283–S1346 (2021).
   Google Scholar
• Hilmi M , MitryE, TurpinAet al. A randomized, non-comparative, phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo) or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): first interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY. J. Clin. Oncol. 40(Suppl. 16), 4148 (2022).
   Web of Science ®Google Scholar
• Leary A , DelucheE, FavierLet al. TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab versus best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum. J. Clin. Oncol. 40(Suppl. 16), TPS5614 (2022).
   Google Scholar
• Brahmer JR , Rodriguez-AbreuD, RobinsonAGet al. KEYNOTE-024 5-year OS update: firstline (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%. Ann. Oncol. 31(Suppl. 4), S1142–S1215 (2020).
   Google Scholar
• Aguilar EJ , RicciutiB, GainorJFet al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann. Oncol. 30(10), 1653–1659 (2019).
   PubMed Web of Science ®Google Scholar
• Herbst RS , GandaraDR, HirschFRet al. Lung Master Protocol (Lung-MAP) – a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin. Cancer Res. 21(7), 1514–1524 (2015).
   PubMed Web of Science ®Google Scholar
• Cristescu R , Aurora-GargD, AlbrightAet al. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J. Immunother. Cancer 10(1), e003091 (2022).
   PubMed Web of Science ®Google Scholar
• Gandara DR , PaulSM, KowanetzMet al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat. Med. 24(9), 1441–1448 (2018).
   PubMed Web of Science ®Google Scholar
• Carbone DP , ReckM, Paz-AresLet al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).
   PubMed Web of Science ®Google Scholar
• Hellmann MD , CiuleanuTE, PluzanskiAet al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Eng. J. Med. 378(22), 2093–2104 (2018).
   PubMed Web of Science ®Google Scholar
• Rizvi NA , HellmannMD, SnyderAet al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
   PubMed Web of Science ®Google Scholar
• Marinelli D , MazzottaM, ScaleraSet al. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Ann. Oncol. 31(12), 1746–1754 (2020).
   PubMed Web of Science ®Google Scholar
• Barve M , BenderJ, PappenBet al. Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients. J. Clin. Oncol. 26(Suppl. 15), 8057 (2008).
   Web of Science ®Google Scholar